Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide for Inflammation at High Altitude
NCT07517068Phase 1Active, not recruiting
- Sponsor
- University of California, Riverside
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute mountain sickness (AMS) and hypoxemia comparing Acetazolamide treatment with Placebo Treatment (2 arms). Primary endpoints: Distributions of circulating immune cell subsets at 1.5 months and Functional characteristics of peripheral immune cells at 2 years. Started Sep 2025; status: active, not recruiting.
02
Drugs
acetazolamide
03
Conditions
acute mountain sickness (AMS)hypoxemia
Beyond the preview
Go deeper on NCT07517068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07517068.